Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

ClinicalTrials.gov ID: NCT03732677

Public ClinicalTrials.gov record NCT03732677. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Study identification

NCT ID: NCT03732677
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 1,063 participants

Conditions and interventions

Conditions

Muscle Invasive Bladder Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 16, 2018 (Actual)
Primary completion: Apr 29, 2024 (Actual)
Completion: Nov 8, 2027 (Estimated)
Last update posted: Oct 15, 2026

2018 – 2027

United States locations

U.S. sites: 18
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35294	—
Research Site	Los Angeles	California	90095	—
Research Site	Palo Alto	California	94304	—
Research Site	New Haven	Connecticut	06520	—
Research Site	Chicago	Illinois	60611	—
Research Site	Geneva	Illinois	60134	—
Research Site	Iowa City	Iowa	52242	—
Research Site	Westwood	Kansas	66205	—
Research Site	Louisville	Kentucky	40202	—
Research Site	New Orleans	Louisiana	70112	—
Research Site	Towson	Maryland	21204	—
Research Site	Ann Arbor	Michigan	48109	—
Research Site	Detroit	Michigan	48201	—
Research Site	New York	New York	10029	—
Research Site	Rochester	New York	14642	—
Research Site	Bethlehem	Pennsylvania	18015	—
Research Site	Burlington	Vermont	05401	—
Research Site	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 170 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03732677, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 15, 2026 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03732677 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →